Amicus, Biogen to collaborate on Parkinson's

Amicus Therapeutics (FOLD) inks a collaboration deal with Biogen (BIIB) for the discovery, development, and commercialization of novel small molecules for the treatment of Parkinson's disease.

This is a preclinical venture. The two companies will seek to discover a new class of small molecules that target the GCase enzyme.

There are no upfront payments to FOLD.

BIIB will fund all discovery, development, and commercialization and will reimburse FOLD for the cost of employees working on the project.

FOLD is eligible for development and regulatory milestones and "modest" royalties. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs